Iron Chelators and Hypoxia Mimetics Inhibit IFNγ-Mediated Jak-STAT Signaling  by Gira, Amy K. et al.
Iron Chelators and Hypoxia Mimetics Inhibit
IFNc-Mediated Jak-STAT Signaling
Amy K. Gira1,2, Andrew P. Kowalczyk1, Yue Feng3 and Robert A. Swerlick1,2
Treatment of cultured cells with iron chelators causes profound changes in gene expression and inhibition of
cytokine signaling pathways, suggesting an important role for iron in inflammation. We have previously shown
the treatment of cells with chelators which preferentially bind iron inhibits IFNg-mediated induction of IFN
regulatory factor 1 in endothelial cells. To define the mechanisms mediating inhibition of IFNg-induced genes,
we examined IFNg-induced signaling pathways in EC after treatment with chelators. Treatment resulted in
inhibition of IFNg-induced STAT1 nuclear translocation. This was associated with inhibition of IFNg-induced
STAT1 phosphorylation and loss of expression of the R1 subunit of the IFNg receptor (IFNgR) complex, without
changes in expression of IFNgR complex subunits. Downregulation of IFNgR1 was not mediated through
alterations in IFNgR1 gene transcription, but was induced by inhibition of IFNgR1 mRNA translation
superimposed on a constitutively high receptor turnover through endosomal degradation. Furthermore,
inhibition of IFNg signaling and downregulation of IFNgR1 was also mediated by nonmetal-binding hypoxia
mimetics and reduced oxygen tensions. These data suggest that the target for chelator effects may be through
iron requirements for oxygen-requiring dioxygenase enzymes.
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INTRODUCTION
Proinflammatory responses of endothelial cells (EC) can be
modulated using a variety of pharmacological agents, the
study of which is an area of intense focus given its potential
for alleviating human disease (Schon et al., 2002). We have
previously demonstrated that iron chelators displayed surpris-
ing anti-inflammatory effects in cultured microvascular EC
in vitro (Koo et al., 2003). The targets for these effects appear
to be multiple and include tumor necrosis factor-a and IFNg
inducible genes such as vascular cell adhesion molecule 1,
and intercellular adhesion molecule 1.
In previous studies, we demonstrated that IFNg-mediated
induction of the transcription factor IFN regulatory factor 1
(IRF-1) was blocked by treatment of EC with agents that
preferentially complex iron (Gira et al., 2003). However,
although the chelator-mediated inhibition of tumor necrosis
factor-g-inducible genes, such as vascular cell adhesion
molecule 1, could be explained by effects on NF-kB
signaling, inhibition of IFNg activated pathways could not
be readily explained on the basis of effects on this pathway.
To address how metal chelators may inhibit IFNg signaling,
we examined chelator sensitive mechanisms involved in
IFNg activation in microvascular EC cells. In this work, we
define unique anti-inflammatory effects of chelators targeting
inhibition of IFNg signaling in EC through downregulation of
IFNg receptors (IFNgR). Furthermore, these effects of metal
chelators appear to act through pathways that are common to
hypoxia and hypoxia mimetics.
RESULTS
DP and DFO inhibit IFNc-mediated STAT1 activation in
microvascular EC cells
As IFNg induces IRF-1 expression via signaling pathways that
result in STAT1 activation and nuclear translocation, we
examined whether IFNg treatment, in the presence or
absence of chelator pretreatment, resulted in changes in
IFNg-induced STAT1 nuclear translocation using electro-
phoretic mobility shift assay (EMSA). Treatment of micro-
vascular EC cells with IFNg (500Uml1 30minutes)
resulted in the formation of a new complex identified on
EMSA that was completely supershifted with anti-STAT1
antibody, Pretreatment of cells for 24 hours with 2-20-
dipyridyl (DP) before IFNg treatment completely inhibited
new complex formation (Figure 1a).
Preincubation of microvascular EC cells with DP for
24 hours resulted in complete loss of IFNg-mediated STAT1
activation as assessed by EMSA whereas shorter treatments
resulted in attenuation but not complete loss of STAT1
activation (Figure 1b). In contrast, DP treatment had no effect
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on NF-kB activation and nuclear translocation (data not
shown; Gira et al., 2003; Koo et al., 2003).
To examine whether STAT1 activation steps proximal to
nuclear translocation are blocked by chelators, we examined
whether DP or desferrioxamine (DFO) inhibited STAT1
phosphorylation. Microvascular EC cells were treated with
DP or DFO for 24 hours before IFNg treatment. Whole-cell
extracts were harvested and expression of phospho-STAT1
was assessed by western blot. DP and DFO inhibited
IFNg-mediated STAT1 phosphorylation in a concentration-
dependent fashion (Figure 2) at doses comparable to those
required to inhibit IRF-1 induction (Gira et al., 2003).
Metal chelators downregulate expression of IFNc receptor 1
IFNg-mediated phosphorylation of STAT1 requires the
functioning of the IFNgR-signaling complex. Binding of IFNg
to this heterodimeric receptor complex consisting of trans-
membrane IFNgR1(a) and IFNgR2(b) chains results in
signaling through associated JAK1 and JAK2 proteins (Pestka
et al., 1997). The inhibition of STAT1 phosphorylation by
chelators could involve alteration of the expression or
function of any one of these participants.
To examine whether the expression of the signaling-
complex proteins was altered by chelators, we treated
microvascular EC cells with DP and examined the cells for
the overall expression of IFNgR1, IFNgR2, JAK1, and JAK2, by
western analysis. Treatment of microvascular EC cells with
DP induced a marked decrease in the expression of IFNgR1
protein whereas it had no effect on the expression of IFNgR2,
JAK1, or JAK2 (Figure 3a). Decreased expression of IFNgR1
protein was detectable by 8 hours and almost complete by
16 hours, a time course consistent with the loss of IFNg
signaling previously observed (Figure 3b).
To further define the role of iron in this effect, we
examined whether treatment of human dermal microvascular
EC (HDMEC) with DFO also altered IFNgR1 expression.
Treatment with iron chelator DFO also induced down-
regulation of IFNgR1 expression (Figure 3c) and DFO-
mediated downregulation was reversed by the addition of
ferric chloride. In addition, loss of IFNgR1 expression was
associated with loss of IFNg induction of intercellular
adhesion molecule 1 in HDMEC (Figure 3d).
To characterize the mechanism involved in IFNgR1
downregulation, we initially examined expression of IFNgR1
gene transcription and steady state levels of IFNgR1 mRNA
using real-time quantitative PCR. Levels of IFNgR1 mRNA
(Figure 3e) were not altered by treatment with chelators,
suggesting that the regulatory events affected by metal
chelators were not at the level of gene transcription or
mRNA stability.
IFNcR1 is a labile protein and its expression is regulated via an
endocytic pathway
The lack of changes in IFNgR1 mRNA after DP treatment
suggested that decreased expression of IFNgR1 protein was
not regulated transcriptionally, but alternatively at the level of
protein translation or protein stability. IFNgR1 might be
rapidly turned over, perhaps via internalization and degrada-
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Figure 1. Dipyridyl inhibits IFNc-mediated STAT1 nuclear translocation.
5A32 HDMEC were treated with IFNg (500Uml130minutes) with or
without pretreatment with DP (500 mM24hours). Nuclear extracts were
isolated as described in materials and methods and activated nuclear STAT
complexes assessed by EMSA. (a) New complex formation was noted in IFNg
treated cells which was blocked with cold competitor oligonucleotide and
shifted with anti-STAT1 antibody, but not antibodies recognizing STAT4, p65,
or p50. New complex formation was completely lost in cells treated with DP.
(b) HDMEC were pretreated with DP for 4, 8, and 24 hours. Inhibition of new
complex formation was seen as early as 8 hours but was complete after
24 hours.
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Figure 2. Iron chelators inhibit IFNc-mediated STAT1 phosphorylation.
5A32 HDMEC were treated with IFNg (500Uml130minutes) with or
without pretreatment with DP (a) or DFO (b) at increasing doses for 24 hours.
Whole-cell extracts were assessed for p-STAT1 expression by western blot.
Both DP and DFO inhibit IFNg-mediated p-STAT1 expression.
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tion. Previous studies have suggested that IFNgR expression is
regulated after ligand binding via trafficking through en-
docytic pathways (Subramaniam and Johnson, 2002).
To define cellular localization of IFNgR, we used
immunofluorescence microscopy. Staining of paraformaldhyde-
fixed and permeabilized, untreated microvascular EC with
antibodies recognizing IFNgR1 did not demonstrate any
clearly recognizable cell surface or vesicular pattern of
staining (data not shown). However, cells pretreated with
chloroquine and then examined similarly demonstrated an
accumulation of material in vesicles that was identified by
anti-IFNgR1 antibody (Figure 4a). This material colocalized
with antibodies recognizing the late endosomal/lysozyme
marker CD63, thus providing evidence of the trafficking of
IFNgR1 through endosomes in a ligand-independent fashion.
Cotreatment with DP modestly decreased the intensity of, but
did not abolish, IFNgR1 staining. These data suggested a
rapid turnover of IFNgR1 and targeting to lysosomes
independent of ligand of chelator treatment.
If DP treatment induced downregulation of IFNgR1
primarily via increased degradation through lysosomes, we
predicted that treatment of microvascular EC cells with the
lysosomal inhibitor chloroquine would block IFNgR1 protein
degradation and rescue cells from chelator-induced IFNgR1
downregulation as has been reported with other proteins such
as VE-cadherin (Kowalczyk et al., 1998). Microvascular EC
cells were treated with DP with and without chloroquine
pretreatment and lysates examined for IFNgR1 expression by
western blot. As noted previously, treatment of microvascular
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Figure 3. Iron chelators downregulate expression of IFNcR1 protein
expression and function. (a) 5A32 HDMEC were treated with DP
(500mM24 hours) and expression of IFNgR1, IFNgR2, JAK1, and JAK2 were
examined by western blot. DP treatment induced decreased expression of
IFNgR1 without comparable effects on other components of the IFNg
signaling complex. (b) HDMEC treated with DP (500 mM) demonstrated time-
dependent downregulation of IFNgR1 (c). DFO treatment also induced
downregulation of IFNgR1, which was reversible with the addition of ferric
chloride. HDMEC were either untreated, treated with DFO
(500mM16 hours), FC (500 mM16 hours), or DFO and FC (both
500mM16 hours). DFO and FC were preincubated together for 30minutes
before addition to cells. (d) Loss of IFNgR1 expression blocks IFNg-mediated
induction of ICAM-1. HDMEC were pretreated with DP
(500Uml116 hours) followed by treatment with IFNg
(500Uml124 hours). (e) DP does not affect IFNgR1 mRNA expression.
HDMEC were treated with DP (500 mM24 hours) and expression of IFNgR1
mRNA was assessed by quantitative PCR.
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Figure 4. IFNcR1 is a labile protein that is constitutively internalized and
degraded through an endosomal pathway. (a) Microvascular EC cells were
treated with chloroquine (100mM) alone (upper panels), or in combination
with DP (500mM16 hours), fixed and stained for expression of IFNgR1 (left
panels) or EEA-1 (middle panels). Right panels represent overlay of IFNgR1
and EEA-1 staining. Cells treated with chloroquine demonstrate vesicular
localization of IFNgR1 staining, which colocalizes with CD63, an endosomal
marker. Cotreatment of cells with chloroquine and DP prevents loss of
IFNgR1 expression. (b) Microvascular EC cells were treated with chloroquine
(100mM16 hours) and/or DP (500mM16hours) and whole-cell extracts
assessed for IFNgR1 expression by western blot. Treatment with DP results in
loss of IFNgR1 expression. Chloroquine treatment results in marked increased
IFNgR1 expression and appearance of lower molecular weight fragments.
Cotreatment with both agents inhibits DP-mediated loss of full-length IFNgR1
expression and also a more modest expression of lower molecular weight
species recognized by anti-IFNgR1 antibody. Bar¼20 mm.
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EC cells with DP resulted in downregulation of expression of
IFNgR1 (Figure 4b). Treatment with chloroquine alone
resulted in both increased expression of full-length IFNgR1
as well as the detection of two lower molecular weight
species. These lower molecular species are likely intermedi-
ate fragments that result from partial degradation of IFNgR1
and retention of these fragments in lysozomes. Pretreatment
of microvascular EC cells with chloroquine before DP
treatment partially prevented IFNgR1 downregulation,
although the levels of both full-length and partially degraded
IFNgR1 protein were decreased from cells treated with
chloroquine alone. These data provide further support to a
rapid turnover via ligand-independent trafficking of IFNgR1
to endocytic vesicles and lysosomes, even in the absence of
chelator treatment. Furthermore, as trafficking to lysosomes
appears to occur even in the absence of DP treatment, the
loss of IFNgR1 expression in DP treated cells appeared to be
most likely mediated by DP-induced changes in synthesis and
not degradation.
DP treatment results in loss of polyribosomes associated with
IFNcR1 mRNA
A key step in the regulation of protein synthesis is to control
the efficiency for mRNA to associate with actively translating
ribosomes. Actively translated mRNA species can be found to
associate with large number of ribosomes, whereas less
actively translated mRNA species tend to carry less translat-
ing ribosomes, or even are sequestered into translationally
dormant messenger ribonucleoprotein particles. To examine
whether chelators inhibited IFNgR1 protein synthesis by
inhibiting mRNA association with polyribosomes, we used
linear sucrose gradient fractionation to analyze the ability for
IFNgR1 mRNA to associate with polyribosomes. Treatment of
microvascular EC cells with DP resulted in a shift of IFNgR1
mRNA from heavy polyribosome-associated fractions into
complexes that are smaller than ribosome subunits thus
sediment into the top fraction of the gradient (Figure 5).
Dissociating polyribosomes with EDTA released the poly-
ribosome associated IFNgR1 mRNA into the same small
complexes, indicating that treatment with chelators-targeted
IFNgR1 translation by sequestration of IFNgR1 mRNA into
translationally inactive messenger ribonucleoproteins.
IFNcR1 expression is downregulated by hypoxia mimetics
To define a mechanism mediating chelator effects on IFNgR1
expression, we considered whether a previously character-
ized iron-dependent mechanism could be involved. As
IFNgR1 mRNA association with polyribosomes was inhibited
in a fashion similar to what has been previously described in
translational controls of ferritin mRNA, one possibility was
that the IFNgR1 mRNA contained an iron responsive element
in its 50UTR which regulated its translation in an iron-
dependent fashion. (Rouault and Klausner, 1997) However,
no consensus or candidate IRE could be identified using the
mfold algorithm.
Additional potential iron-requiring targets are the iron-
dependent dioxygenases, which regulate the stability of
hypoxia-inducible factors (HIF) 1a and 2a. In the presence
of appropriate cofactors (oxygen, iron, and a-ketoglutarate),
HIFa subunits are targeted for degradation after oxidative
modifications. HIF instability is mediated by a family of prolyl
hydroxylases, which require the presence of iron, oxygen,
and a-ketoglutarate for activity (Schofield and Ratcliffe,
2005). If iron chelator-mediated inhibition of dioxygenases
was involved in the downregulation of IFNgR1, we predicted
that other nonmetal-binding hypoxia mimetics that also
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Figure 5. DP induces loss of association of IFNcR1 mRNA with polyribosomes: microvascular EC cells were treated with DP (500 lM16 hours) and
cytoplasmic extracts fractionated on sucrose gradients. Expression of IFNgR1 mRNA in each fraction was measured using real-time quantitative PCR and
relative content of each fraction calculated and compared to untreated control cells (far left panel) and extracts treated with EDTA (far right panel). 30% of
IFNgR1 mRNA was associated with polyribosomal fractions in control cells whereas less than 10% was found in polyribosome contain fractions in DP-treated
cells, comparable to the distribution observed in cytoplasmic fractions treated with EDTA.
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inhibit dioxygenases should have comparable effects on
IFNgR1 expression as iron chelators.
To test this hypothesis, we treated microvascular EC cells
with dimethyloxallyl glycine (DMOG), a 2-oxoglurate
mimetic and inhibitor of prolyl hydroxylase, and examined
the expression and function of IFNgR1. Intracellularly,
DMOG is converted to N-oxalylglycine, a structural analo-
gue of and competitive inhibitor of 2-oxoglutarate, which will
inhibit 2-oxoglutarate-dependent dioxygenase function
(Baader et al., 1994; Hanson et al., 2003). Consistent with
this hypothesis, treatment of EC with DMOG resulted in a
dose-dependent inhibition of IFNg-mediated STAT1 activa-
tion and downregulation of IFNgR1 (Figure 6a and b).
Additionally, treatment of EC with hypoxia also resulted in
decreased expression of IFNgR1 (Figure 6c) comparable to
cells treated with chelators or hypoxia mimetics.
DISCUSSION
We previously demonstrated that chelators inhibit IFNg-
mediated induction of IRF-1 in EC, and in this work we have
extended our observations by defining specific mechanisms
mediating inhibition of IFNg signaling pathways. Treatment
of microvascular EC cells with chelators DP or DFO results in
decreases of IFNg-mediated STAT activation. These effects
were found to be associated with a marked downregulation
of IFNgR1, a key component of the IFNgR signaling complex,
without affecting the overall expression of other components
of the IFNgR signaling complex.
Previous studies defining effects of chelators on tumor
necrosis factor-a-mediated gene expression showed that the
targets for inhibition were transcriptional, blocking induction
of vascular cell adhesion molecule 1 gene transcription
despite having no effect on NF-kB activation and nuclear
translocation(Koo et al., 2003). In contrast, the mechanism
mediating the targeted downregulation of the IFNgR1 did not
involve alterations in IFNgR1 gene transcription or mRNA
stability because neither steady state levels of IFNgR1 mRNA
nor nascent heterogeneous nuclear RNA were not altered by
chelator treatment. These data are consistent with previous
studies examining the regulation of expression of the IFNgR1
gene with promoter analysis of IFNgR1 demonstrating
features consistent with a housekeeping gene (Pestka et al.,
1997) and with the constitutive expression found in micro-
vascular EC cells.
These data suggested that chelators alter expression of
IFNgR1 in microvascular EC cells through influencing protein
synthesis or trafficking. Previous studies have demonstrated
that IFNgR1 can be internalized in a ligand-dependent
fashion and targeted to nuclear and endosomal compart-
ments.(Sadir et al., 2001; Subramaniam and Johnson, 2002)
Other previous studies showed that treatment with chlor-
oquine blocked IFNgR turnover, suggesting endosomal
targeting. This was consistent with current immunofluores-
cence microscopy studies of chloroquine-treated cells show-
ing IFNgR1 primarily localized to vesicular cytoplasmic
bodies that coexpressed the lysosomal marker CD63. Our
studies provide evidence that IFNgR1 may also be turned
over relatively rapidly in a ligand-independent fashion as
well. Polyribosome analysis demonstrated that DP treatment
results in loss of association of IFNgR1 mRNA with
polyribosomes, consistent with inhibition of protein transla-
tion. These findings are consistent with a model where loss of
IFNgR1 synthesis results in rapid loss of expression, except
when degradation of IFNgR1 protein in lysosomes is blocked.
Under these circumstances, fine control of the receptor
expression can be achieved with small changes in protein
synthesis.
Control of IFNgR expression has been examined in some
detail in T cells and T cell lines (Skrenta et al., 2000).
Alterations in expression have been examined looking mostly
at cell surface expression and have identified dynamic
regulation primarily through the IFNgR2 subunit (Rigamonti
et al., 2000; Bernabei et al., 2003). Furthermore, recent
studies have implicated iron in the regulation of IFNgR in
human T lymphocytes (Regis et al., 2006). However, these
observations are to some degree at odds with our observa-
tions of IFNgR on other cell types. Treatment of T cells with
iron resulted in transferrin-mediated internalization of IFNgR
and receptor downregulation. In contrast, low-dose DFO
treatment (10 mM) resulted in upregulation of IFGgR2 and
restoration of IFNg responsiveness in selected T cell lines. In
contrast, treatment of microvascular EC cells with iron
chelators resulted in loss of IFNg signaling associated with
marked downregulation of IFNgR1. The DFO-mediated
effects required substantially higher concentrations to block
tumor necrosis factor and IFNg signaling (200–500 mM) than
the 10 mM concentrations described in the work of Regis et al.
(2006). Concentrations of DFO required to mimic hypoxia
and block HIF prolyl hydroxylases range from 100 to 500 mM,
and are substantially higher than those concentrations used in
the aforementioned T-cell studies. Given the differences in
cells examined and endpoints, it is not possible to completely
reconcile differences between observations in T cells and EC
without further studies.
The target for metal chelators in EC is not yet completely
defined. Our observations regarding iron and its role in the
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Figure 6. DMOG inhibits IFNc-mediated STAT1 phosphorylation and
downregulates IFNcR1 expression. (a) HDMEC were treated with increasing
doses of DMOG for 24 hours and stimulated with IFNg
(500Uml130minutes). (b) HDMEC were treated with increasing doses of
DMOG for 24 hours and whole-cell lysates were assayed for IFNgR1, JAK1,
and JAK2 by western blot. (c) HDMEC were treated with hypoxia (see
Materials and Methods) for 6 and 24 hours and whole-cell lysates assayed for
IFNgR1 expression by western blot.
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control of IFNgR1 translation might point to regulation via
iron-dependent interactions with the 50 or 30 UTRs of the
IFNgR1 mRNA, which could contain regulatory elements
that that function in an iron-responsive fashion. This could
be similar to what has been described for the translation of
the ferritin and transferrin genes (Rouault and Klausner,
1997). However, no sequences could be identified that
contained motifs previously described as essential for these
functions.
Alternatively, we considered other iron-based targets that
might control protein translation. Iron chelators, such as DP
or DFO, may exert effects by acting as hypoxia mimetics,
inhibiting activity of iron-dependent dioxygenase enzymes
such as prolyl and asparagyl hydroxylases (Schofield and
Ratcliffe, 2005). This family of enzymes requires iron,
oxygen, and a-ketoglutarate as cofactors in reactions that
attach hydroxyl groups to key prolines and asparagines or
induce oxidative demethylation of histones. Consistent with
possibility is the observation that DMOG, a nonmetal-
binding antagonist of a-ketogluratate (Hanson et al., 2003),
and reduced oxygen tension also inhibited IFNg-mediated
signaling and downregulated IFNgR1 expression in a manner
essentially identical to iron chelators.
The studies using chelator compounds clearly have their
limitations. Although both DFO and DP have very high
affinities for iron, both DP and DFO may chelate other metals
including copper and zinc. It is possible that these agents act
in our model through iron-independent mechanisms. How-
ever, the similar effects of nonmetal-binding hypoxia
mimetics, such as DMOG and hypoxia, on IFNgR1 expres-
sion argues for the involvement of an iron as part of an iron-
dependent dioxygenanse.
The significance of these observations may be multifold.
Although our original hypothesis proposed that inhibition of
cytokine-mediated signaling occurred via antioxidant effects,
studies of vascular cell adhesion molecule 1 induction
demonstrated that metal binding appeared to be more
important than antioxidant activity (Koo et al., 2003). The
studies reported in this article provide evidence that the
involvement of iron may be via a pathway, which shares a
mechanism with pathways regulated through oxygen tension
as well.
By altering cytokine responsiveness, iron chelators or aKG
analogues may be useful pharmacological agents to regulate
inflammatory responses. It is possible that dioxygenases, such
as prolyl hydroxylases, acting as sensors for oxygen tension
and metabolic state of certain cells may be important in the
regulation of responses to proinflammatory cytokines such as
IFNg. HIF hydroxylases are the best-characterized iron- and
aKG-regulated enzymes, but recent studies have also
identified the cupins, a large family of metal, aKG, and
oxygen-dependent enzymes which play both enzymatic and
structural roles. Members of the cupin family have been most
intensively studied relating to plant physiology, but newly
identified members are now recognized as crucial in gene
regulation (Dunwell et al., 2004). More clearly defining
specific mechanisms will be important to fully exploit
therapeutic potential for these agents.
MATERIALS AND METHODS
Cell culture
Immortalized microvascular EC (5A32) were utilized and passaged
as described previously (Ades et al., 1992; Koo et al., 2003).
Hypoxic conditions were achieved were achieved using a Billups-
Rothenberg modular incubator (Billups-Rothenberg Inc., Del Mar,
CA) chamber filled with a mixture of 95% N2 and 5% CO2. Hypoxic
conditions were confirmed using disposable anaerobic indicator
(Becton Dickinson and Company, Franklin Lakes, NJ).
Reagents and antibodies
The iron chelators DP and DFO (Syvertsen and McKinley-McKee,
1984; Horky et al., 1998; Liu and Hider, 2002; which respectively
bind ferrous iron (Fe2þ ) and ferric iron (Fe3þ ), chloroquine, and
cycloheximide were obtained from Sigma-Aldrich (St Louis, MO).
DMOG was purchased from Cayman Chemical (Ann Arbor, MI).
Recombinant human IFNg was purchased from R & D Systems Inc.
(Minneapolis, MN). Mouse monoclonal anti-CD63 (mouse IgG1)
was obtained from the Developmental Studies Hybridoma Bank
(University of Iowa, clone H5C6). Rabbit polyclonal anti-human
IFNgR1 (C-terminal domain), anti-human IFNgR2 (C-terminal
domain), anti-human JAK1, anti-human JAK2, and rabbit polyclonal
anti-human STAT4 antibodies sc-485 (C terminal) and sc-485 (N
terminal) were obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Rabbit polyclonal anti-human STAT1 and anti-human phospho-
STAT2 were purchased from Upstate Biotechnology (Waltham, MA).
Western blot
Whole-cell lysates were prepared as described previously (Naik
et al., 1997) and extracts were resolved on a 10% SDS-PAGE using
reducing concentrations. After transfer to hybond ECL nitrocellulose
(Amersham Pharmacia Biotech, Uppsala, Sweden), the gel was
stained with Ponceau S (Sigma-Aldrich) to verify uniform loading
and transfer. Membranes were blocked with 5% bovine serum
albumin in tris-buffered saline-Tween 20 (50mmol/l Tris-HCl,
150mmol/l NaCl, 0.1% Tween 20, pH 7.4) overnight and
subsequently incubated with primary antibodies for 1 hour at room
temperature. The membrane was washed with tris-buffered saline-
Tween 20 three times and incubated for 1 hour at room temperature
with the appropriate goat anti-rabbit horseradish peroxidase-
conjugated secondary antibody. Subsequently, the membrane
was washed three times with tris-buffered saline-Tween 20 and
analyzed by enhanced chemiluminescence (ECL reagent; Amersham
Pharmacia Biotech).
Measurement of mRNA and heterogeneous nuclear RNA
expression
Total RNA was isolated with TriReagent (Sigma) from microvascular
EC cells according to the manufacturer’s instructions. cDNA was
prepared using the Superscript Preamplification System for 1st Strand
cDNA Synthesis (Gibco, Carlsbad, CA) using the random primer
protocol. Real-time PCR was done using SYBR green technology
with Perkin-Elmer 5700 Gene-Amp Detection System with IFNgR1
primers (forward sequence CATCACGTCATACCAGCCATTT and
reverse sequence CATGCCTGGAACTGTTGCT). Data were normal-
ized with primers for housekeeping gene. Relative quantities were
determined by generating a standard curve from dilutions of cDNA
containing the message of interest. Data were then expressed as fold
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increase over control. All primers were synthesized by Emory
University Microchemical Facility.
EMSA
Nuclear extracts were prepared and binding reactions were
performed as described previously (Naik et al., 1997).
Cell-based ELISA
Expression of intercellular adhesion molecule 1 and Class I was
assessed using a cell-based ELISA system as previous described
(Swerlick et al., 1991).
Sucrose gradient fractionation
Linear sucrose gradients (15–45%; w/v) were employed to fractionate
cytoplasmic extracts derived from control cells, DP-treated cells, or
EDTA-treated cellular extracts using published procedures (Feng
et al., 1997). Each gradient was fractionated by upward replacement
and collected into 12 fractions. Total RNA was isolated from each
fraction by phenol/chloroform extraction followed by real-time
quantitative PCR. Percentages of mRNA found in each fraction were
calculated as (quantity mRNA in fraction)/(total quantity mRNA in all
12 fractions) 100.
Immunofluorescence microscopy
Microvascular EC cultured on gelatin-coated glass coverslips were
rinsed in phosphate-buffered saline (phosphate-buffered saline
containing Ca2þ and Mg2þ ) and were fixed in 3.7% paraformalde-
hyde in phosphate-buffered saline followed by extraction in 0.5%
Triton X-100 in phosphate-buffered saline (Kowalczyk et al., 1998).
IFNgR1 was detected using rabbit polyclonal anti-IFNgR1 (Santa
Cruz Biotechnology Inc.). The localization of late endosomes/
lysosomes was monitored using a mouse monoclonal anti-CD63
antibody (Transduction Laboratories, Lexington, KY). Appropriate
species cross-absorbed secondary antibodies conjugated to various
Alexa Fluors (Molecular Probes, Eugene, OR) were used for dual-
label immunofluorescence. Control experiments were carried out
routinely to verify that fluorescence was not due to secondary
antibody cross-reactivity. Microscopy was carried out using a Leica
DMR-E fluorescence microscope equipped with narrow band pass
filters and a Hammamatsu Orca camera. Images were captured,
pseudo-colored, and processed using Open Lab software (Improvi-
sion Inc., Lexington, MA).
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